Press Releases HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Market Closed - Toronto S.E. Other stock markets 01:59:08 2024-06-04 pm EDT			5-day change	1st Jan Change
3.77 ^CAD	+1.34%		+0.27%	-4.56%

May. 28	HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study	MT
May. 28	HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment	May. 28	AQ
HLS Therapeutics Announces Q1 2024 Financial Results	May. 09	AQ
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call	Apr. 25	AQ
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 09	AQ
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 08	AQ
HLS Therapeutics Announces Fiscal 2023 Financial Results	Mar. 14	AQ
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call	Feb. 29	AQ
HLS Announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	Feb. 07	AQ
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan	Feb. 06	AQ
HLS Therapeutics Announces CFO Departure	Dec. 18	AQ
HLS - New REDUCE-IT Analyses Show Vascepa Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline	Nov. 15	AQ
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline	Nov. 14	AQ
HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid	Nov. 09	AQ
HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call	23-10-26	AQ
HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference	23-09-06	AQ
HLS Therapeutics Announces Updates to its Credit Agreement	23-08-14	AQ
HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results	23-08-10	AQ
HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call	23-08-03	AQ
HLS Therapeutics Announces Updates to its Board of Directors	23-06-22	AQ
HLS Therapeutics Reports Annual Meeting Results	23-06-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Press Releases

Filters